The only thing anticipated this quarter is initial results. To me this means a general indication of how the new signal is performing. With prior tests of the original signal already showing significant reduction of inflammation in the liver, I would definitely expect some positive initial results with the new signal. The full report with all the specifics, what would be submitted to the FDA and hopefully be peer reviewed, will come down the road, IMO.
The Company is evaluating the therapeutic potential of its new electroceutical technology in prevention of heart failure following myocardial infarction. The Company now anticipates initial results from its ongoing pre-clinical study in the second quarter of 2017.
The Immunotronics™ platform harnesses magnetically-induced electrical field pathways in cells and tissues to elicit an anti-inflammatory response. In early testing, the technology has already been shown to be a very potent anti-inflammatory device in a pharmaceutical 'gold standard' model of inflammation. The device could be used to treat the early stages of NASH to prevent liver scarring and would compete with Allergan's recent acquisitions in the space.
News 
Market Data 
Discover 
AI
